Substance / Medication

Penciclovir

Overview

Active Ingredient
penciclovir
RxNorm CUI
59839

Indications

Penciclovir cream is a deoxynucleoside analog HSV DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in adults and children 12 years of age or older.

Labeler: Torrent Pharmaceuticals LimitedUpdated: 2025-02-04T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Penciclovir cream is contraindicated in patients with known hypersensitivity to the product or any of its components.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats.
Thomasy Sara M, Maggs David J, Moulin Nicole K et al. · Am J Vet Res · 2007
PMID: 17975982RCT
Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery.
Lv Qingzhi, Yu Aihua, Xi Yanwei et al. · Int J Pharm · 2009
PMID: 19429280Observational
Microemulsion-based hydrogel formulation of penciclovir for topical delivery.
Zhu Weiwei, Guo Chenyu, Yu Aihua et al. · Int J Pharm · 2009
PMID: 19463929Observational
Simultaneous determination of aciclovir, ganciclovir, and penciclovir in human plasma by high-performance liquid chromatography with fluorescence detection.
Dao Yi-jun, Jiao Zheng, Zhong Ming-kang · J Chromatogr B Analyt Technol Biomed Life Sci · 2008
PMID: 18468495Observational
Development and validation of a new reversed-phase ion pairing liquid chromatographic method with fluorescence detection for penciclovir analysis in plasma and aqueous humor.
Schenkel F, Rudaz S, Daali Y et al. · J Chromatogr B Analyt Technol Biomed Life Sci · 2005
PMID: 16140045Observational
Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines.
Leary Jeffry J, Wittrock Robert, Sarisky Robert T et al. · Antimicrob Agents Chemother · 2002
PMID: 11850259ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Penciclovir (substance)
SNOMED CT
386939003
UMLS CUI
C0164815
RxNorm CUI
59839
Labeler
Torrent Pharmaceuticals Limited

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.